Safety Analysis Of The Randomized Phase Ii Study Of Folfoxiri Plus Cetuximab Versus Folfoxiri Plus Bevacizumab As The First-Line Treatment In Metastatic Colorectal Cancer With Ras Wild-Type Tumors: The Deeper Trial (Jaccro Cc-13)

Takanori Watanabe,Akihito Tsuji,Manabu Shiozawa,Hirofumi Ota,Hironaga Satake,Taichi Yabuno,Junichi Hasegawa,Mitsugu Kochi,Dai Manaka,Tamotsu Sagawa,Masahito Kotaka,Yutaro Kubota,Yu Sunakawa,Takashi Sekikawa,Masato Nakamura,Masahiro Takeuchi,Wataru Ichikawa,Masashi Fujii

JOURNAL OF CLINICAL ONCOLOGY（2021）

引用 12|浏览6

暂无评分

摘要

86Background: Triplet regimens, FOLFOXIRI, combined with bevacizumab (bev) or panitumumab have been shown to be superior in terms of early tumor shrinkage (ETS) and depth of response (DpR) compared...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要